Introduction. Recently published data of several large multicenter studies using 6% HES 130/0,4-0,42 in adult patients has come to the conclusion about its careful administration in patients with compromised renal function and/or coagulation. Systematic reviews of starches use in children have shown that there are few statements about reducing the risk of death administering crystalloids or colloids in pediatric intensive care. Objective. To determine the safety of 6% Hydroxyethylstarch (HES) 130/0.42 in a balanced electrolyte solution in term newborns with severe hypoxic-ischemic encephalopathy. Methods. The article presents the results of the own study for the safety of 6% HES 130/0.42 in the treatment of full-term infants with severe hypoxic-ischemic encephalopathy.28 and 90-day mortality were analyzed, as well as the possible kidneys complications in accordance with the pRIFLE classification in infants received 6% HES 130/0.42 at a dose of 10 ml/kg of body weight compared to infants being treated by 0.9% NaCl at a dose of 20 ml/kg of body weight, as well as the control group, carried out by a routine therapy without administration of additional amounts of crystalloids and /or colloids. Results. In the 28th and 90th days of observation there was no deaths recorded in the studying or control groups. All the children survived and were discharged for out patient care. There were no statistically significant differences between the study and control groups regarding the possible complications from kidney basing on pRIFLE score. Conclusions. Using of 6% HES 130/0.42 at 10 ml/kg of body weight in term newborns with severe hypoxic-ischemic encephalopathy is safe compared with normal saline. Moderate doses of 6% HES 130/0.42 can be used in full-term newborns with hypoxic-ischemic encephalopathy when the fluid load of crystalloids was not effective.